A B S T R A C T Treatment of human platelets with purified bovine Factor VIII caused three types of aggregation: (a) primary agglutination; (b) secondary aggregation involving the platelet release reaction; and (c) super-aggregation, in which the platelets were gathered into only a few large clumps. Removal of calcium ions or treatment with p-hydroxymercuriphenyl sulfonate blocked the release reaction, but not primary agglutination or super-aggregation. Platelets treated with formalin were not aggregated by ADP, thrombin, or collagen, but were agglutinated by bovine Factor VIII, although they did not show super-aggregation. Formalin-treated platelets were agglutinated by phytohemagglutinin P less extensively and less rapidly than by bovine Factor VIII. Treatment of platelets and Factor VIII with neuraminidase released 60 and 53%, respectively, of the sialic acid residues without affecting the agglutination reaction or the procoagulant activity of the Factor VIII. Agglutination was inhibited by high salt concentrations, dextran sulfate, and heparin. During agglutination, both the procoagulant and platelet-agglutinating activities of Factor VIII became bound to the platelet surface.
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INTRODUCTION
Factor VIII is a high molecular weight glycoprotein complex with at least two activities. It is an essential component of the intrinsic pathway of blood coagulation (antihemophilic factor activity) and is required for the normal hemostatic function of the blood platelets (von Willebrand's factor activity).
Hemophiliacs treated with bovine Factor VIII preparations develop thrombocytopenia (1), presumably because of in vivo platelet aggregation. Early reports This work has been presented in part to the National Conference on Thrombosis and Hemostasis, American Heart Association, November, 1974.
Received for publication 18 October 1974 and in revised form 14 April 1975. indicated that bovine fibrinogen aggregated human platelets (2, 3) but Forbes and Prentice (4) showed that the aggregating activity in bovine cryoprecipitate was eluted from an agarose column with Factor VIII, and not with fibrinogen. Griggs, Cooper, Webster, Wagner, and Brinkhous (5) have reported using 0.25 M CaCI2 to dissociate the coagulant activity of bovine Factor VIII from its platelet-aggregating activity, and have found the aggregating activity to be associated with the high molecular weight fraction. The analogy between the platelet-aggregating activity of bovine Factor VIII and the ability of human Factor VIII to correct the bleeding tendency in von Willebrand's disease (von Willebrand factor activity) is strong, but has not been definitely established.
Aggregation of human platelets by bovine Factor VIII may have some analogy to the role of human Factor VIII in the normal platelet aggregation mechanism. Patients with von Willebrand's disease have long bleeding times and decreased platelet retention in glass bead columns (6) . This disease is associated with reduced Factor VIII procoagulant activity and a decrease in the amount of circulating Factor VIII protein, determined immunologically (7) .
The antibiotic ristocetin causes platelet aggregation in normal platelet-rich plasma (PRP).' Platelet aggregation induced by ristocetin is generally defective in von Willebrand's disease (8) . Platelets washed to remove Factor VIII are not aggregated by ristocetin. Aggregation can be restored by the addition of purified human Factor VIII (9), but not by other plasma components. Platelets from patients with Bernard-Soulier syndrome are not aggregated by ristocetin (10) or by bovine Factor VIII (11) .
In this paper we use the term "aggregation" to mean clumping of platelets in which the platelets actively participate. Aggregation is blocked by metabolic inhibitors. "Agglutination" refers to a passive clumping, as in antibody-induced agglutination.
We report the effects of purified bovine Factor VIII on human platelets both in PRP and in suspensions of platelets treated with formalin. The effects of several inhibitors and chemical modifications of the Factor VIII were studied to determine the molecular basis for the interaction between Factor VIII and platelets.
METHODS
Buffers. Tris-saline buffer was 0.01 M Tris-HCl-0.15 M NaCl, pH 7.4. Phosphate-saline buffer was 0.01 M sodium phosphate buffer-0.15 M NaCl, pH 6.5.
Platelets. Blood was collected by venipuncture into oneninth vol of 3.8% sodium citrate. PRP was prepared by centrifugation at 250 g for 10 min at room temperature. PRP was used within 6 h of the time the blood was drawn. Outdated platelet concentrates were a gift from the Penn-Jersey Regional Red Cross Blood Program.
Formalin-treated platelets were prepared by mixing PRP or platelet concentrates with an equal volume of Tris-saline buffer containing 8 mg/ml formaldehyde (Tris-saline buffer: formalin, 98: 2 vol/vol) and stored at 4VC until needed.
The platelets were then centrifuged at 1,500 g for 10 min and resuspended in phosphate-saline buffer. Centrifugation and resuspension were repeated twice. Platelets were finally suspended to approximately 8 X 109 platelets/ml in phosphate-saline buffer, then diluted 1: 18 in Tris-saline buffer for aggregation studies. These formalin-washed platelets could be stored at 0C for at least a week without losing their ability to be agglutinated by bovine Factor VIII.
Platelet aggregation was studied in the apparatus described by Mills and Roberts (12) , and in a Payton aggregometer (Payton Instrument Co., Buffalo, N. Y.) modified to increase the stirring speed to 1,500-1,600 rpm, so that comparable aggregation traces (24) . Heparin was covalently bound to agarose (Biogel A 1.5m, Bio-Rad Laboratories, Richmond, Calif.) with cyanogen bromide (25) .
RESULTS
Platelet aggregation by bovine Factor VIII. The traces in Fig. 1 compare the effect of thrombin and bovine factor VIII on platelets in fresh citrated PRP. At low concentrations of Factor VIII (2 Ig/ml), two phases of clumping were observed, the second of which was associated with the release of ["C]5HT from the platelets. Release Increasing the concentration of bovine Factor VIII caused a reduction in the amount of 5HT released, and this reduced degree of release was further inhibited by EDTA and by PHMBS. With the highest concentration of bovine Factor VIII, there was very little release, although clumping was rapid and extensive. All of the platelets were present in a few large aggregates, in contrast to the numerous small aggregates formed at lower concentrations. This gave rise to a characteristic "spiky" appearance of the trace, the spikes being caused as the one or two large aggregates passed through the light path of the aggregometer.
The formation of these characteristic large aggregates by bovine Factor VIII we have termed "superaggregation". This phenomenon is not blocked by 12.5 mM EDTA or 1.25 mM PHMBS and does not require the platelet release reaction to occur. The only other agent with which we have seen this characteristic aggregation response in EDTA-treated platelets is ristocetin in the presence of human Factor VIII.
Comparison of Factor VIII-induced and lectin-induced aggregation. Phytohemagglutinin P (PHAP) is a plant lectin that binds to the N-acetylgalactosamine residues of certain glycoproteins. PHAP causes platelet agglutination (27) PRP was incubated with antimycin A (5 ,ug/ml) and 2-deoxy-D-glucose (20 mM) at 37'C. At the indicated times, samples were removed and transferred to aggregometer cuvettes, and aggregation was initiated with either ADP (5 ALM) or bovine Factor VIII (7 Ag/ml).
I (28) . PHAP, like Factor VIII, caused agglutination in the presence of EDTA (Fig. 2) , but there were several differences between the effects of these two agents. Agglutination by PHAP was neither as extensive nor as rapid as the response to Factor VIII ( Fig. 2) , nor was super-aggregation seen with PHAP. Both experiments shown in Fig. 2 were done with the same batch of PRP, so the aggregometer traces are directly comparable. Essentially all of the platelets were clumped in all of these traces. The differences in percent transmission after clumping apparently represent differences in the size and structure of the aggregates.
Effects of metabolic inhibitors. Incubation of fresh citrated PRP with antimycin A (5 /Ag/ml) and 2-deOxy-D-glucose (20 mM) causes a decrease in the metabolic ATP content of platelets (29) , which is reflected in a decrease in the adenylate energy charge as determined by the method of Mills (30) . We observed that the amount of ATP decreased from about 80% of the metabolically active pool to less than 30% within 30 min. As shown in Fig. 3 , incubation of platelets with antimycin and deoxyglucose abolished the response to ADP, but the platelets were still clumped by bovine Factor VIII. These results are similar to those obtained by Solum (3) , who studied aggregation induced by a preparation of bovine platelet fibrinogen.
The (Fig. 4B ).
Formalin-treated platelets are also agglutinated by polylysine (32) . Fig. 5 shows that low concentrations of highly polymerized polylysine (mol wt = 195,-000) caused rapid agglutination. Higher concentrations were not as effective. Similar observations were made with histone and with polylysine of mol wt 85,000.
Polylysines of lower molecular weight caused microscopic agglutination, but not enough to alter the transmittance of the suspensions in the aggregometer. Neither histone nor polylysine caused super-aggregation in PRP.
Role of free thiol groups. Thiol groups on the platelet surface are essential for platelet aggregation by ADP and thrombin (33) . Fig. 6 shows that 2.5 mM NEM or PHMBS, both of which react with thiol groups, blocked the aggregation of platelets by ADP, without blocking the agglutination induced by bovine Factor VIII. PHMB (2 mM), however, was able to block both ADP and Factor VIII-induced aggregation. A similar action of PHMB on ristocetin-induced agglutination had been reported by Kattlove and Gomez (34) .
Pretreatment of Factor VIII for up to 80 min with NEM or PHMBS had no effect on its platelet-agglutinating activity and caused only a slight decrease in its procoagulant activity (Table I ). The lack of effect of these reagents on Factor VIII is to be expected since Legaz et al. (14) reported that there are no free thiol 8.4 pg/mg (35) and 10Lg/mg (36) for washed platelets. Incubation of formalin-treated platelets with purified neuraminidase caused rapid release of 60% of the sialic acid. The remaining residues were not removed, even after prolonged incubation. Neuraminidase treatment did not cause spontaneous aggregation of formalin-treated platelets, in contrast to its effect on washed native platelets. Removal of 60% of the sialic acid residues from the formalin-washed platelets did not inhibit agglutination by bovine Factor VIII (Fig.  7A) . The rate of agglutination was, in fact, slightly increased after this treatment, perhaps because of a consequent decrease in net negative charge on the platelet surface.
Acid hydrolysis of purified bovine Factor VIII indicated a total sialic acid content of 24 pg/mg protein, in agreement with the value of 21 pg/mg found by Schmer et al. (13) . Purified neuraminidase released 53% of the total sialic acid from Factor VIII without altering its coagulant activity. Neuraminidase treatment of Factor VIII also caused no change in its ability to agglutinate formalin-treated platelets (Fig. 7B) , or to agglutinate native platelets in PRP.
Vermylen, Donati, de Gaetano, and Verstraete (37) observed that human Factor VIII, treated with 1 U/ml of a commercial neuraminidase preparation, developed the ability to aggregate human platelets in PRP directly, without the addition of ristocetin. We have observed this phenomenon, under the same conditions. (1) Dextran sulfate (1.2 /Ag/ml) was added to formalin-treated platelets, followed by addition of Factor VIII (7.6 /Ag/ml). (2) Factor VIII (7.6 ,g/ml) was added to platelets, followed by addition of dextran sulfate (1.2 Ag/ml).
mechanism from the action of bovine Factor VIII. When purified human Factor VIII (0.2 mg/ml) was treated with 0.016 U/ml of purified neuraminidase for 2 h at 370C, we did not observe the development of any agglutinating activity toward formalin-treated platelets. Sufficient homogenous human Factor VIII was not available for measurement of released sialic acid, but under similar conditions maximal release of sialic acid from bovine Factor VIII was achieved. Role of charged groups. The primary interaction between bovine Factor VIII and human platelets may be mediated by charged groups. High sodium chloride concentrations, which interfere with electrostatic interactions, inhibited the agglutination induced by Factor VIII (Fig. 8) . Addition of sodium chloride to formalin-washed platelets already agglutinated by Factor VIII caused reversal of the agglutination. Negatively-charged polymers can inhibit platelet agglutination induced by bovine Factor VIII. Low concentrations (< 1 /Lg/ml) of dextran sulfate completely blocked Factor VIII-induced agglutination (Fig. 9A) . Dextran sulfate also inhibited agglutination by polylysine and histone. Higher concentrations of Factor VIII could overcome the inhibition caused by dextran sulfate, resulting in complete agglutination. Addition of dextran sulfate to formalin-treated platelets agglutinated by Factor VIII completely reversed the agglutination (Fig. 9B) .
Very similar effects were seen with heparin, except that concentrations in the range of 0.1-1.0 mg/ml were required for complete inhibition of agglutination. However, amino groups on heparin give it a lower net charge density than dextran sulfate. Also, the molecular weight of heparin is considerably lower than that of the dextran sulfate used.
The presence of amino groups on heparin allows it to be linked to agarose by the cyanogen bromide method (38) . Bovine Factor VIII was passed through a column of heparin-agarose without losing either its procoagulant or platelet-agglutinating activities. This suggests that heparin does not bind strongly to Factor VIII.
Binding of Factor VIII to formalin-treated platelets. Agglutination of platelets by bovine Factor VIII involves a direct binding of the Factor VIII to platelets, as demonstrated in the experiment described in Fig. 10 Factor VIII, the supernate that remained after agglutination contained only 54% of the initial Factor VIII coagulant activity (trace A). It was apparent that platelet-agglutinating activity was also removed from the supernate, because when more platelets were added to the supernate (trace B), agglutination occurred at a slower rate and to a decreased extent. After the second adsorption, only 28% of the initial coagulant activity remained in the supernate, and platelet-agglutinating activity was almost completely gone (trace C).
Dextran sulfate (1 Ag/ml) does not inhibit the coagulant activity of Factor VIII, but completely blocks its platelet-agglutinating activity. In the presence of dextran sulfate, binding of Factor VIII coagulant activity to formalin-treated platelets was greatly decreased (Table II) . When the platelet pellets were resuspended in buffer containing dextran sulfate, significant Factor VIII coagulant activity could be recovered, demonstrating that Factor VIII had been adsorbed rather than inactivated. Significantly less Factor VIII was bound to the platelets in the presence of dextran sulfate than in its absence. DISCUSSION Addition of highly purified bovine Factor VIII to fresh human citrated PRP causes three different types of aggregation phenomena: (a) primary agglutination, (b) secondary aggregation involving the platelet release reaction, and (c) super-aggregation, in which all of the small platelet aggregates are gathered into very large aggregates. These three reactions may occur almost simultaneously under certain conditions. DifInteraction of Factor VIII with Platelets Primary agglutination. Agglutination of paraformaldehyde-treated platelets by bovine Factor VIII or by ristocetin in the presence of human Factor VIII was first described by Allain and Cooper (32) . The use of formalin-treated platelets has several advantages for the investigation of agglutination. Outdated blood bank platelets can be used, and a single batch gives reproducible responses over several days. The responses are not complicated by the occurrence of the release reaction or of super-aggregation, and washing removes the bulk of the plasma proteins without reducing the stability of the suspended platelets.
Thiol groups are necessary for the aggregation of platelets by ADPR and thrombin and are readily blocked by NEM and PHMBS (33) . Since NEM and PHMBS do not block Factor VIJI-induced aggregation, it seems unlikely that the thiol groups involved in ADP-and thrombin-induced aggregation are also involved in Factor VIII-induced aggregation. However, PHMB, a mercurial thiol reagent similar in structure to PHMBS, inhibited agglutination by both bovine Factor VIII and by ristocetin in the presence of human Factor VIII. The latter observation has been reported by Kattlove and Gomez (34) .
It is doubtful whether bovine Factor VIII' has any reactive thiol' groups. If the molecular weight of the subunits of Factor VIII is approximately 150,000 (13), our results with DTNB titration would imply less than one available -SH group for every four 'subunits. NEM-reacting groups on bovine Factor VIII, if present, are not involved in either its procoagulant or its platelet-agglutinating activity. Low concentrations (3 X 101 M) of PHMB had no -effect on either of-the activities of Factor VIII. High concentrations of PHMBS (10 mM) had no effect on the platelet-agglutinating activity of Factor VIII, and only slightly decreased its procoagulant activity. These observations are in apparent conflict with those of Austen (39) , who reported strong inhibition of the procoagulant activity of bovine Factor VIII by several sulfhydryl reagents. In particular, he reported that Factor VIII was 75% inhibited by 3 X 10-M PHMB,' although it was less sensitive to higher concentrations.
Platelets from patients with Bernard-Soulier syndrome have less sialic acid than normal (35) , and these platelets are not aggregated by bovine fibrinogen (10) or by purified bovine Factor VIII (11) , suggesting that sialic acid might play a role in the aggregation of platelets by Factor VIII. However, we found that 60% of the sialic acid could be removed from formalintreated platelets without inhibiting the agglutination by bovine Factor VIII.
Levy-Toledano, Caen, Halmos, and Mester (40) reported that treatment of bovine plasma with neuraminidase destroyed much of the platelet-agglutinating activity without affecting Factor VIII procoagulant activity. We observed, on the contrary, that neuraminidase treatment of purified bovine Factor VIII could release 53% of its sialic acid without altering either procoagulant activity or ability to aggregate human platelets.
Agglutination of platelets by bovine Factor VIII involves direct adsorption of Factor VIII onto the platelet surface, since both Factor VIII procoagulant and platelet-agglutinating activities were removed from the solution during agglutination of the platelets (Fig. 10) . In agreement with Griggs et al. (5), we observed that relatively more agglutinating activity was bound to the platelet than coagulant activity (Table II) . From the amount of Factor VIII removed from the solution, and by assuming a molecular weight of about 2 X 108 (13) , it can be estimated that the addition of sufficient Factor VIII to cause agglutination of all the platelets is accompanied by the adsorption of approximately 2,000 molecules of Factor VIII/platelet. In contrast, Tollefsen, Feagler, and Majerus (28) reported that the platelet has approximately 300,000 receptors for PHAP, and that approximately 25% of these must be occupied for half-maximal release of platelet nucleotides.
Several lines of evidence suggest that the interaction between bovine Factor VIII and platelets is an electrostatic one. High molecular weight polycations like polylysine and histone can cause agglutination of formalin-treated platelets in a manner similar to bovine Factor VIII. Negatively charged molecules like dextran sulfate and heparin inhibit the agglutination caused by Factor VIII and by polylysine and can cause disaggregation of platelets agglutinated by Factor VIII. High salt concentrations, which would interfere with electrostatic interactions, also inhibit Factor VIIIinduced agglutination. Super-aggregation. Super-aggregation is the gathering together of the small platelet aggregates, formed in the early stages of aggregation, into a few very large aggregates. It does not require the release reaction, and is not inhibited by EDTA, PHMBS, or a mixture of antimycin and deoxyglucose.
A certain degree of metabolic integrity in the platelet is required for super-aggregation, since this phenomenon is blocked by treating the platelets with NEM or with formaldehyde. The presence of plasma proteins is not required, since super-aggregation can also be observed upon addition of Factor VIII to washed platelets.
Super-aggregation did not occur with thrombin or with very high concentrations of PHAP, but could be induced by ristocetin in the presence of human Factor VIII. This is apparently a unique characteristic of Factor VIII-induced platelet aggregation and may represent a previously undescribed functional capacity of the platelet.
